Literature DB >> 15664743

A stability indicating LC method for rivastigmine hydrogen tartrate.

B Mallikarjuna Rao1, M K Srinivasu, K Praveen Kumar, Neelu Bhradwaj, R Ravi, Pradeep K Mohakhud, G Om Reddy, P Rajender Kumar.   

Abstract

An isocratic, reversed-phase liquid chromatographic (RPLC) method was developed for the quantitative determination of Rivastigmine hydrogen tartrate, a cholinesterase inhibitor in bulk drugs and in pharmaceutical dosage forms. The developed method is also applicable for the related substance determination of Rivastigmine hydrogen tartrate in bulk drugs. The chromatographic separation was achieved on a Waters X Terra RP18 (250 mm x 4.6 mm, 5 microm) column using aqueous 0.01 M sodium-1-heptane sulphonate (pH: 3.0 with dilute phosphoric acid)-acetonitrile (72:28, v/v) as a mobile phase. The chromatographic resolution between Rivastigmine and its potential impurity, namely (S)-3-(1-dimethylaminoethyl) phenol (Imp 1) was found to be greater than four. Forced degradation studies were performed for Rivastigmine hydrogen tartrate bulk drug using acid (0.5 N hydrochloric acid), base (0.5 N sodium hydroxide), oxidation (3% hydrogen peroxide), heat (60 degrees C) and UV light (254 nm). No degradation was observed for Rivastigmine hydrogen tartrate except in base hydrolysis and the formed degradation product was found to be Imp 1. The mass balance of Rivastigmine hydrogen tartrate was close to 100 in all the stress conditions. The limit of detection (LOD) and limit of quantification (LOQ) of Imp 1 were found to be 100 and 300 ng/ml, respectively, for 10 microl injection volume. The percentage recovery of Imp 1 in bulk drug sample was ranged from 95.2 to 104.3. The active pharmaceutical ingredient was extracted from its finished dosage form (capsule) using water. The percentage recovery of Rivastigmine hydrogen tartrate was ranged from 99.2 to 101.3 and 98.6 to 101.5 in bulk and pharmaceutical formulation samples, respectively. Rivastigmine hydrogen tartrate sample solution and mobile phase were found to be stable for at least 48 h. The developed method was validated with respect to linearity, accuracy, precision, robustness and forced degradation studies prove the stability indicating power of the method.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15664743     DOI: 10.1016/j.jpba.2004.09.041

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  6 in total

1.  In situ-forming oleogel implant for rivastigmine delivery.

Authors:  Anda Vintiloiu; Michel Lafleur; Guillaume Bastiat; Jean-Christophe Leroux
Journal:  Pharm Res       Date:  2007-08-12       Impact factor: 4.200

2.  In Vitro and in Vivo Optimization of Phase Sensitive Smart Polymer for Controlled Delivery of Rivastigmine for Treatment of Alzheimer's Disease.

Authors:  Lindsey Lipp; Divya Sharma; Amrita Banerjee; Jagdish Singh
Journal:  Pharm Res       Date:  2020-01-15       Impact factor: 4.200

3.  A RP-HPLC Method for the Analysis of Neostigmine Methylsulfate and Process-Related Impurities, Forced Degradation Studies, in the Injection Formulation.

Authors:  Manali Parab; Vaishali A Shirsat; Yogita M Kodgule; Mandar Kodgule
Journal:  Int J Anal Chem       Date:  2021-05-11       Impact factor: 1.885

4.  Preparation and Characterization of Rivastigmine Transdermal Patch Based on Chitosan Microparticles.

Authors:  Mohsen Sadeghi; Fariba Ganji; Seyyed Mojtaba Taghizadeh; Bahram Daraei
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

5.  A Stability Indicating HPLC Assay Method for Analysis of Rivastigmine Hydrogen Tartrate in Dual-Ligand Nanoparticle Formulation Matrices and Cell Transport Medium.

Authors:  Naz Hasan Huda; Bhawna Gauri; Heather A E Benson; Yan Chen
Journal:  J Anal Methods Chem       Date:  2018-03-01       Impact factor: 2.193

6.  High-performance liquid chromatographic determination of rivastigmine in human plasma for application in pharmacokinetic studies.

Authors:  Hossein Amini; Abolhassan Ahmadiani
Journal:  Iran J Pharm Res       Date:  2010       Impact factor: 1.696

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.